



Maternal Metformin Intervention during Obese Glucose Intolerant Pregnancy Affects Adiposity in Young Adult Mouse Offspring in a Sex-Specific Manner

Josca M. Schoonejans^{1*}, Heather L. Blackmore¹, Thomas J. Ashmore¹, Catherine E. Aiken², Denise S. Fernandez-Twinn¹, Susan E. Ozanne^{1*}

¹ Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories, University of Cambridge, Cambridge, CB2 0QQ, United Kingdom

² Department of Obstetrics and Gynaecology, University of Cambridge, Cambridge, CB2 0SW, United Kingdom

* Correspondence: jms297@medschl.cam.ac.uk and seo10@cam.ac.uk; Tel.: +44 1223 336784

Abstract: Background: Metformin is commonly used to treat gestational diabetes mellitus. This study investigated the effect of maternal metformin intervention during obese glucose-intolerant pregnancy on gonadal white adipose tissue (WAT) of 8-week-old male and female mouse offspring. Methods: C57BL/6J female mice were provided with control (Con) or obesogenic diet (Ob) to induce pre-conception obesity. Half the obese dams were treated orally with 300mg/kg/d metformin (Ob-Met) during pregnancy. Gonadal WAT depots from 8-week-old male and female mouse offspring were investigated for adipocyte size, macrophage infiltration and mRNA expression of pro-inflammatory genes using RT-PCR. Results: Gestational metformin attenuated adiposity in obese dams and increased gestation length without correcting offspring *in-utero* growth restriction and catch-up growth caused by maternal obesity. Despite similar body weight, Ob and Ob-Met offspring of both sexes showed adipocyte hypertrophy in young adulthood. Male Ob-Met offspring had increased WAT depot weight ($p<0.05$), exaggerated adipocyte hyperplasia ($p<0.05$ vs Con and Ob offspring), increased macrophage infiltration measured via histology ($p<0.05$) and mRNA expression of *F4/80* ($p<0.05$). These changes were not observed in female Ob-Met offspring. Conclusions: Maternal metformin intervention during obese pregnancy causes excessive adiposity, adipocyte hyperplasia and WAT inflammation in male offspring, highlighting sex-specific effects of prenatal metformin exposure on offspring WAT.

Keywords: gestational diabetes; fetal programming; metformin; maternal obesity; white adipose tissue; sex differences

1. Introduction

The prevalence of obesity is rising at sufficiently rapid rates such that over 50% of women of child-bearing age in the UK are currently overweight or obese [1]. Obesity is not only associated with adverse metabolic and cardiovascular events in the adult female [2], but when present during pregnancy also has long-term ‘programming effects’ on exposed offspring that increase their risk of obesity, insulin resistance, type 2 diabetes and the metabolic syndrome [3].

Women with obesity are four times more likely to develop gestational diabetes mellitus (GDM) during pregnancy [4]. Metformin is the first-line pharmacological treatment for GDM in many countries including the UK when lifestyle interventions are ineffective and its use has been increasing world-wide [5,6]. In pregnancy, metformin improves glucose tolerance in women with GDM, and metformin treatment is associated with lower gestational weight gain compared to insulin or placebo in GDM or obese glucose tolerant women, respectively [7,8]. Its oral administration, lack of requirement for refrigerated storage and cost-effectiveness also makes it more appropriate than insulin for use in low-resource settings. Therefore, it is plausible that metformin use in pregnancy might offer a suitable intervention to mitigate or negate the adverse effects of an obese diabetic intrauterine environment on offspring health globally. However, metformin readily crosses the placenta [9] and offspring follow-up in human randomised controlled trials investigating maternal metformin treatment remains sparse, with few studies reporting offspring outcomes beyond infancy [10–15]. However, the fact that several studies report increased adiposity in children exposed to maternal metformin treatment in pregnancy warrants further investigation into long-term effects [10,12,13]. Animal studies are therefore essential to determine the direct and indirect effects of maternal and *in utero* metformin exposure on offspring adiposity, adipose tissue biology and metabolic health. Moreover, animal studies allow the investigation of potentially sexually dimorphic effects whereas human follow-up studies are often insufficiently powered to perform this analysis.

In our well-established mouse model of maternal diet-induced obesity [16], dams are fed an obesogenic diet high in both fat and sugar before mating and are consequently obese, hyperleptinaemic and hyperinsulinaemic at conception and develop glucose intolerance in pregnancy [16–18]. It was previously found that male offspring of obese dams develop obesity from 12 weeks of age, while adipocyte hypertrophy is present from as early as 8 weeks of age [16,19,20]. We and others have shown that the programming effects of maternal obesity on male rodent offspring adiposity and adipose tissue function can be ameliorated by maternal exercise intervention [17,21,22]. Although effects of early life exposure to metformin on offspring body composition have been reported in several rodent models [23–29], the effects of clinically relevant maternal metformin intervention exclusively during obese glucose intolerant pregnancy (and not lactation) on offspring WAT have not been studied. Furthermore, growing evidence indicates that programming effects can be sexually dimorphic, with males and females responding differently or showing a different time course of response to a suboptimal *in utero* environment [30], highlighting the importance of including both male and female offspring in this study.

This study therefore aimed to investigate the effect of maternal metformin intervention during obese glucose intolerant pregnancy on 8-week-old offspring gonadal WAT using a mouse model of diet-induced obesity. Importantly, since it has emerged that there can be sex specific effects of *in utero* exposures, this study included both male and female offspring. We report that maternal obesity causes gonadal adipocyte hypertrophy, which is not corrected by the metformin intervention. Instead, the metformin intervention increased adipocyte hyperplasia, macrophage infiltration and gonadal WAT inflammation in male but not female offspring.

Citation: Schoonejans, JM.; Blackmore, HL.; Ashmore, TJ. [Aiken CE](#), Fernandez-Twinn, DS; Ozanne, SEO. Maternal metformin intervention during obese glucose intolerant pregnancy affects adiposity in young adult mouse offspring in a sex-specific manner. *Int. J. Mol. Sci.* **2021**, *22*, x. <https://doi.org/10.3390/xxxxx>

Academic Editor: Firstname Lastname

Received: date

Accepted: date

Published: date

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

2. Results

2.1 Metformin Attenuates Fat Mass in Diet-Induced Obese Dams

Ob and Ob-Met dams were fed an obesogenic diet prior to mating, and hence had higher body weight and fat mass than Con dams in late gestation (Table 1). The metformin intervention decreased maternal body weight and fat mass (but not lean mass) at E15.5. Maternal obesity caused a reduction in litter size (from 7 to 6 pups per litter, Table 1). This reduction was not prevented by maternal metformin treatment (Table 1). Maternal obesity also led to decreased pup weight on postnatal day 2 (PN2) (from 1.9 to 1.6 gram per pup, Table 1). This growth restriction was not prevented by maternal metformin administration (Table 1). Dams fed the obesogenic diet had fewer pups than control and their pups had a lower body weight at PN2 (Table 1). Maternal metformin treatment did not prevent the reduction in litter size born to obese dams and did not prevent the reduction in pup weight on PN2 despite increasing the increased gestation length observed in metformin-treated obese pregnancies (Table 1).

Table 1. Dam body composition and pregnancy outcomes.

* $p<0.05$, ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$ vs Con, # $p<0.05$, ## $p<0.01$, ### $p<0.001$ vs Ob using one-way ANOVA with Tukey's multiple comparison test, Kruskal-Wallis test for non-parametric data (gestation length and litter size) or ANOVA performed on log-transformed data (PN2 weight). E15.5 = embryonic day 15.5. ns = not significant. PN2 = postnatal day 2.

Dams at E15.5	Con n=15	Ob n=13	Ob-Met n=6-7	p-value
Body weight (g)	36.0 ± 0.7	49.0 ± 0.8***	44.9 ± 1.2***, #	<0.0001
Lean mass (g)	23.9 ± 0.7	24.7 ± 0.6	23.9 ± 0.6	ns
Fat mass (g)	4.5 ± 0.3	15.6 ± 0.6***	12.4 ± 0.6***, ##	<0.0001
Fat mass (%)	12.5 ± 0.7	31.7 ± 0.9***	27.6 ± 0.9***, ##	<0.0001
Pregnancy outcome	n=24-31	n=30-33	n=20-26	
Gestation length (d)	20 [19-20]	20 [20-21]	21 [20.3-21]***, ##	<0.0001
Litter size (no pups)	7.0 [6.0-9.0]	6.0 [5.0-7.0]**	6.0 [5.0-7.0]*	0.0015
PN2 weight (g/pup)	1.9 ± 0.04	1.6 ± 0.04****	1.7 ± 0.04***	<0.0001

2.2 Maternal Metformin Treatment Induces Adiposity in Male but Not Female Offspring

Pups born to Ob dams were lighter at PN2 but displayed catch-up growth leading to higher pup weights than controls by PN14, and this difference remained at PN21. This was not corrected by the metformin intervention (Figure 1A). After weaning there were no differences in body weight between any of the three groups up to 8 weeks of age (Figure 1B). However, the weights of the gonadal, intraperitoneal, and subcutaneous WAT depots at 8 weeks of age were significantly increased in male Ob-Met offspring (Figure 1C). This was not observed in female Ob-Met offspring (Figure 1D).

2.3 Metabolic Health Is Not Affected by Maternal Obesity or Metformin Exposure

Serum insulin was not significantly different between groups in either male (Con 50 ± 6, Ob 67 ± 6, Ob-Met 73 ± 10 pmol/L, $p=0.1697$, one-way ANOVA) or female offspring (Con 77 ± 15, Ob 67 ± 7, Ob-Met 52 ± 4 pmol/L, $p=0.1417$, one-way ANOVA). Similarly, there was no difference in glucose tolerance as measured by intraperitoneal glucose tolerance test in male (Con 1340 ± 51, Ob 1448 ± 57, Ob-Met 1343 ± 67 AUC, $p=0.3463$, one-way ANOVA) or female offspring (Con 1209 [1183-1321], Ob 1274 [1106-1379], Ob-Met 1235 [1160-1416] AUC, $p=0.9920$, Kruskal-Wallis test).




Figure 1. Offspring growth and adiposity in 8-week-old offspring.

(A) growth trajectory of neonatal offspring ($n=26\text{--}33$ independent litters per group, sexes combined). $****p<0.0001$ vs Con vs Ob, $\#p<0.05$, $###p<0.001$ Con vs Ob-Met using two-way ANOVA with Tukey's multiple comparison test. (B) post-weaning body weight trajectory in male and female offspring until 8 weeks of age ($n=10\text{--}14$ independent litters per group). (C-D) weight of white adipose tissue (WAT) depots collected at 8 weeks of age relative to offspring body weight ($n=8\text{--}10$ independent litters per group). Outlier was excluded from (C) iWAT and sWAT; female Ob (Grubb's method, outlier excluded values 1.03% and 1.45% respectively). $*p<0.05$ using one-way ANOVA with Tukey's multiple comparison test. gWAT = gonadal depot, iWAT = intraperitoneal depot, rWAT = retroperitoneal depot, sWAT = subcutaneous depot. Con (circles, solid line) = offspring of control-fed dams, Ob (squares, dashed line) = offspring of obese dams, Ob-Met (triangles, dotted and dashed line) = offspring of obese metformin-treated dams. Panels B-D: Closed symbols denote male offspring, open symbols denote female offspring.

2.4 Gonadal WAT Cellularity Is Altered by Maternal Obesity and Metformin Intervention

Male and female Ob and Ob-Met offspring showed gonadal adipocyte hypertrophy indicated by the rightward shift in the adipocyte size distribution compared to Con offspring (Figure 2A and 2C, $p<0.0001$ for the interaction between the maternal environment and adipocyte size, two-way ANOVA). This was particularly apparent in the larger adipocyte range, although male Ob-Met offspring also showed an increase in small adipocytes (Figure 2A, left). Maternal obesity increased the estimated adipocyte number in male but not female offspring, and this was exaggerated by exposure to maternal metformin treatment with male offspring of obese metformin treated dams having significantly more adipocytes than male offspring of obese (and control) dams (Figure 2B).

120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143




Figure 12. Cellularity of 8-week-old gonadal adipocytes.

(A) adipocyte size distribution in male (left) and female (right) 8-week-old offspring. (B) estimated adipocyte number in the collected gonadal white adipose tissue (WAT) depot. * $p<0.05$, *** $p<0.0001$ using one-way ANOVA with Tukey's multiple comparison test. (C) representative images of H&E-stained sections used for cell size analysis. Con (circles, solid line) = offspring of control-fed dams, Ob (squares, dashed line) = offspring of obese dams, Ob-Met (triangles, dotted and dashed line) = offspring of obese metformin-treated dams. Closed symbols denote male offspring, open symbols denote female offspring. n=9–14 independent litters per group. Outlier was excluded from (B); male Con (Grubb's method, outlier excluded value 6.28×10^6).

2.5 Maternal Metformin Introduces Gonadal WAT Inflammation in Male Offspring

Male Ob-Met offspring showed increased CLS in adipose tissue indicating a pro-inflammatory signature of the gonadal WAT (Figure 3A-B). This was not seen in female

144
145
146
147
148
149
150
151
152
153

154
155
156

offspring. Accordingly, expression of the macrophage marker *F4/80* was specifically increased in male Ob-Met offspring compared to both Con and Ob offspring WAT (Figure 3C). *Cd11c* (a pro-inflammatory M1-type macrophage marker) expression was not affected by maternal obesity or metformin treatment. Overall, *F4/80* and *Cd11c* expression was lower in female compared to male WAT.




Figure 13. Inflammation in gonadal white adipose tissue.

(A) presence of crown-like structures (CLS) in gonadal white adipose tissue (WAT) of 8-week-old male (left) and female (right) offspring, expressed as percentage area of the WAT tissue and as the number of CLS divided by the number of adipocytes in the section ($n=10\text{--}15$ independent litters per group). * $p<0.05$ using one-way ANOVA with Tukey's multiple comparison test. (B) representative images of H&E-stained sections used for CLS analysis. (C) mRNA expression of macrophage markers in gonadal WAT relative to the expression of housekeeper gene *Ppia* and the male

157
158
159
160
161

162
163
164
165
166
167
168
169

Con group (n=7–10 independent litters per group). * $p<0.05$, *** $p<0.001$, **** $p<0.0001$ for the main effect of sex (S), interaction between sex and the maternal environment (X) or Tukey's multiple comparison using two-way ANOVA. Outlier was excluded from (A) CLS density; female Con (Grubb's method, outlier excluded value 0.46%) and (A) %adipocytes with CLS; male Con (Grubb's method, outlier excluded value 1.19%). From (C) *F4/80* two data points were excluded due to pipetting errors (male Con and female Ob). From (C) *Cd11c* one data point was excluded due to pipetting errors (female Con).

3. Discussion

This study showed that maternal metformin treatment during obese pregnancy decreased maternal fat mass and body weight in late gestation, but failed to correct the decreased litter size, growth restriction with catch-up growth phenotype and adipocyte hypertrophy in offspring exposed to maternal obesity. Moreover, in 8-week-old male offspring maternal metformin intervention exaggerated the adiposity phenotype characterised by excessive adipocyte hyperplasia, macrophage infiltration and expression of pro-inflammatory genes. This was not observed in female offspring

Metformin is known to reduce body weight in non-pregnant type 2 diabetic patients [31], and an effect of metformin to lower gestational weight gain is a common observation in human trials in GDM, polycystic ovary syndrome (PCOS) and obese women [8,32,33]. Our findings of lower body weight and fat mass, consistent with a protective effect of metformin on diet-induced obesity in late gestation, are therefore in accordance with human data, supporting the validity of our model in assessing other effects of metformin treatment during pregnancy including the potential long-term effects of metformin exposure *in utero* on offspring health. As metformin can cross the placenta and enter the fetal circulation attaining similar circulating concentrations to those in the mother, the need for long-term follow up studies has been highlighted [34]. Since these studies are both challenging to carry out and take many years in humans, animal models are important to address this question.

Maternal obesity during pregnancy is associated with increased risk of both small and large for gestational age babies [35]. Consistent with previous studies in the model [16,36,37], we observed growth restriction followed by catch-up growth in offspring exposed to maternal obesity. The combination of low birth weight and accelerated postnatal growth is associated with long-term adverse effects on offspring cardiometabolic health in human studies [38–41] and animal models [42,43]. The metformin intervention did not correct (or worsen) this pattern of early growth. However, our study is the first to report that metformin intervention in the obese mouse dam increased gestation time by one day. Therefore, the equivalent growth restriction observed in both Ob and Ob-Met pups, despite the delay in parturition, might suggest metformin-exposed fetuses would be further growth restricted compared to non-exposed fetuses if assessed on the same gestational day. ~~This again would be consistent with observations in humans that suggest that metformin treatment in gestational diabetic pregnancies is associated with decreased birth weight compared to those treated with insulin [44]. Although usually interpreted as beneficial (prevention of macrosomia), this may reflect relative growth restriction that is masked by the obesogenic glucose intolerant environment. Accordingly, we showed in a recent meta-analysis that decreased birth weight observed in metformin treated human CDM pregnancies is followed by increased postnatal growth leading to heavier infants compared to insulin treated CDM [44]. Similarly, a placebo controlled trial in PCOS women showed excessive postnatal growth in metformin exposed offspring with body weight and BMI diverging from the placebo arm from 6 months of age [12].~~

The mechanism by which metformin causes adiposity in male offspring is unclear. Metformin is known to activate AMPK, causing inhibition of mTOR, decreased cell proliferation, suppression of protein synthesis and cell cycle arrest [34]. Such a mechanism acting on fetal tissue could explain the relative growth restriction observed which is masked in terms of birthweight due to the delay in parturition. Providing metformin in

obese pregnancy but not lactation may thus reflect a model of growth restriction (due to metformin) with catch-up growth (following metformin removal at birth) similar to studies in which recuperated offspring displayed rapid post-natal growth following *in utero* low-protein exposure [42]. This was also proposed by Salomäki *et al.* who drew comparison between their model of gestational metformin treatment to chow-fed dams and developmental programming by maternal undernutrition [26]. Indeed, when looking at studies investigating male offspring adiposity in non-transgenic rodent models (including the current study), metformin was only detrimental to offspring body composition in situations where this cellular ‘starvation’ was followed by restored or increased energy balance in lactation, whereas continued metformin treatment or switching to a healthy diet postnatally was associated with protective effects [23,25,26]. Whether this relates to direct effects of metformin signalling on fetal development or indirectly through effects on maternal metabolism is unclear. Combined with the increased gestation length in this study and the human data summarised above, this suggests that metformin may adversely affect intrauterine development, in particular for male offspring.

At 8 weeks of age body weight and weight of both visceral (epididymal, intraperitoneal and retroperitoneal) and subcutaneous WAT depots were not different between Con and Ob offspring despite evidence of gonadal adipocyte hypertrophy in both sexes, in accordance with previous reports in male offspring [19]. In contrast, maternal metformin treatment introduced male-specific increased adiposity, while female offspring were unaffected. The increased adiposity in male Ob-Met compared to Ob offspring was likely driven by hyperplasia since adipocyte size was unaffected by the metformin intervention. This early life hypercellularity may predispose offspring to becoming obese later in life by increasing life-long lipid-storage capacity of WAT. In addition to being increased in mass, the hypertrophic gonadal WAT of males exposed to metformin *in utero* displayed increased CLS density and mRNA expression of the macrophage marker F4/80 indicative of enhanced macrophage infiltration. This was not seen in Ob offspring indicating a more progressive WAT dysfunction phenotype in Ob-Met offspring despite similar levels of hypertrophy, a known stimulus for macrophage invasion [44]. The percentage of adipocytes surrounded by CLS, a marker of adipocyte death [44,45], was also increased in Ob-Met compared to Ob offspring. This suggests that *in utero* metformin exposure increased adipocyte death rate in male Ob-Met WAT, leading to recruitment of immune cells, phagocytosis of necrotic adipocytes and production of pro-inflammatory mediators. The increased prevalence of CLS in Ob-Met gonadal WAT may be related to the increased hyperplasia since ‘obesity-induced adipocyte death’ has been suggested as the limiting factor to adipocyte hypertrophy and may underlie the switch from hypertrophic to hyperplastic adiposity [44]. Inflammation is a major contributor to adipose tissue insulin resistance. However, no adverse metabolic phenotype was observed in Ob-Met offspring at this age. This is not surprising as WAT inflammation is known to precede systemic hyperinsulinaemia [46] suggesting metabolic alterations may develop at a later age.

Female offspring were relatively protected against programmed adiposity in this study with no effects of either maternal obesity or metformin on weights of the visceral WAT depots. Female 8-week-old offspring also showed lower expression of pro-inflammatory genes compared to males, consistent with reports that basal cytokine and chemokine expression is higher in male compared to female WAT [47]. In contrast to males, there was no maternal environment effect on CLS formation in female offspring, indicating sexually dimorphic susceptibility to WAT inflammation in a programming context. This is in accordance with previous reports showing that maternal high fat feeding in pregnancy leads to macrophage invasion in chow-fed male offspring while female offspring required postnatal high fat diet to show upregulated pro-inflammatory gene expression. Even then, the phenotype was milder than in high fat diet-fed males [48]. The mechanisms underlying the sex differences in our study are unknown, but anti-inflammatory actions of oestrogen in female offspring are suggested as one explanation for this sexual dimorphism [48]. Sexual dimorphism in a developmental programming context is becoming

increasingly recognised, with male offspring often more vulnerable to suboptimal *in utero* exposures than female offspring and subsequently displaying earlier and/or more severe phenotypes in adulthood. This may be related to sexually dimorphic patterns and timing of development, different hormonal intrauterine and postnatal environments and the observation that males grow faster *in utero* than females [49,50].

This again would be The murine data we report here is broadly consistent with observations the limited data available in humans. We showed in a recent meta-analysis of human randomised controlled trials that suggest that metformin treatment in gestational diabetic pregnancies is associated with decreased birth weight compared to those treated with insulin [51]. Although usually interpreted as beneficial (prevention of macrosomia), this may reflect relative growth restriction that is masked by the obesogenic glucose intolerant environment. Accordingly, we showed in a recent meta-analysis that decreased birth weight observed in metformin treated human GDM pregnancies is followed by increased postnatal growth leading to heavier infants compared to insulin-treated GDM [51]. Similarly, a placebo-controlled trial in PCOS women showed excessive postnatal growth in metformin exposed offspring with body weight and BMI diverging from the placebo arm from 6 months of age [12]. The longest human follow-up of metformin-treated GDM pregnancies to date is from the MiG trial in Australasia. In 2011, this trial reported increased adiposity in two-year-old metformin-exposed offspring. Since no detectable change was seen in visceral fat mass at this age, the authors proposed that this might reflect expansion of the more metabolically beneficial subcutaneous depot [52]. Our current animal study however does not support depot-specificity but instead shows a global adiposity phenotype involving both subcutaneous and visceral depots, the latter of which was also shown by another mouse study [26]. Therefore, it is interesting to note that further follow-up from the MiG trial has since shown that adiposity in 9-year-old offspring was indeed globally increased [10]. Furthermore, our meta-analysis of GDM intervention trials also confirmed that compared to insulin, the lower birth weight and accelerated postnatal growth in metformin-exposed babies leads to childhood adiposity [51], consistent with the current mouse study.

Similar to findings in a GDM context, a placebo-controlled trial in PCOS women showed excessive postnatal growth in metformin-exposed offspring with body weight and BMI diverging from the placebo arm from 6 months of age [12]. Moreover, further offspring follow-up of offspring born to metformin-treated PCOS women up to 10 years of age showed similar findings of increased overweight and obesity were reported in prenatally metformin exposed children in placebo-controlled trials in PCOS women [12,13], with an increased proportion of metabolically abnormal obese children in the metformin arm. In contrast, trials in obese glucose tolerant women failed to show a relationship between metformin exposure and offspring adiposity at least up to 4 years of age [8,14,53], highlighting the importance of longer-term follow-up of metformin-exposed offspring.

In addition to the different clinical indications, it is important to note that the timing of metformin administration differs between women treated for GDM (in the second or third trimester) and those with PCOS or type 2 diabetes (before or at conception) or studies in non-diabetic obese women (end of the first trimester). However, the common outcome of increased offspring adiposity in the context of PCOS and GDM suggests that exposure during the last trimester is critical in relation to effects on adiposity. Unfortunately, m

Female offspring were relatively protected against programmed adiposity in this study with no effects of either maternal obesity or metformin on weights of the visceral WAT depots. Female 8 week old offspring also showed lower expression of pro-inflammatory genes, consistent with reports that basal cytokine and chemokine expression is higher in male compared to female WAT [50]. In contrast to males, there was no maternal environment effect on CLS formation in female offspring, indicating sexually dimorphic susceptibility to WAT inflammation in a programming context. This is in accordance with

~~previous reports showing that maternal high fat feeding in pregnancy leads to macrophage invasion in chow fed male offspring while female offspring required postnatal high fat diet to show upregulated pro inflammatory gene expression. Even then, the phenotype was milder than in high fat diet fed males [51]. Anti inflammatory actions of oestrogen in female offspring are suggested as one explanation for this sexual dimorphism [51].
ost human studies are not sufficiently powered to analyse potential sexual dimorphism in offspring outcomes. The paucity of long-term offspring follow-up in humans means that more evidence is required to determine potential critical time windows of exposure, sexual dimorphism in fetal responses as well as the interaction with maternal metabolic status.~~

331
332
333
334
335
336
337
338
339
340

In conclusion, maternal metformin treatment during obese pregnancy decreased maternal fat mass in late gestation, providing a less obese intrauterine environment for developing fetuses and consistent with beneficial effects on maternal physiology. However maternal metformin treatment did not prevent fetal growth restriction, despite an increase in gestation length, or the postnatal catch-up growth phenotype in offspring of obese dams. These findings suggest beneficial effects in maternal physiology do not necessarily translate to improved physiology in the offspring. Furthermore, we observed sex-specific effects of maternal metformin on offspring adiposity, with exposed males demonstrating increased adiposity and adipose tissue inflammation that was not observed in the females. These findings highlight the presence of sexually dimorphic responses to *in utero* exposures and the need to consider immediate as well as postnatal effects of treatments during pregnancy on mother and child. Given the importance of ageing in exaggerating programmed phenotypes and in the development of metabolic disease pathology, it is imperative that these offspring are followed up to determine whether these alterations in adipose biology in young adult life become pathological in later life.

341
342
343
344
345
346
347
348
349
350
351
352
353
354
355

4. Materials and Methods

356

4.1 Animal model

357

All mouse work was performed according to the Home Office Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012, after ethical review by the University of Cambridge Animal and Welfare Ethical Review Board. As previously described [17], female C57BL/6J mice were randomly assigned to either a standard laboratory chow (RM1, 7% sugars, 3% fat) or a high fat diet (10% sugars, 20% fat) supplemented with sweetened condensed milk (55% sugar, 8% fat) and vitamin and mineral pre-mix (AIN-93G-MX, Special Diets Services, UK) from weaning. After 6 weeks they were mated for a primary pregnancy to ensure breeding effectiveness. Obese dams were mated for the experimental pregnancy when they reached a critical threshold of 12g absolute fat mass as measured by non-invasive Time-Domain Nuclear Magnetic Resonance (TD-NMR, Bruker Minispec LF series, Bruker Optik GmbH, Germany), whereas control dams remained below 5g absolute fat mass at mating. Dams were fed their respective diets ad libitum throughout pregnancy and lactation. Half of obese dams were treated orally with 300mg/kg/d metformin-hydrochloride supplemented in the condensed milk from one week pre-mating until embryonic day 19 (E18.5). This clinically relevant dose has previously been used in murine models and equates to a dose similar to those provided to pregnant women [26]. Body composition of dams in all three groups was measured by TD-NMR on E15.5. Litter size was standardised to six pups per litter on PN2. Male and female offspring were weaned onto RM1 at PN21 and housed in littermate pairs of the same sex until culling at 8 weeks of age using rising CO₂ concentration. Excised adipose tissues from fed animals or following a 16 hour fast were formalin-fixed or snap-frozen on dry ice, respectively.

358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381

4.2 Gene expression

Gonadal adipose tissue was lysed on ice in QIAzol Lysis Reagent (Qiagen, USA) using the TissueRuptor II (Qiagen). RNA was extracted using the miRNeasy MiniKit (Qiagen) with DNase digestion (RNase-Free DNase Set, Qiagen) according to the manufacturer's protocols. RNA concentration was determined using a NanoDrop 1000 Spectrophotometer (ThermoScientific, UK) and RNA quality was assessed using gel electrophoresis. cDNA was generated using the HiCapacity RT kit (Applied Biosystems, USA) with addition of RNase inhibitor (Applied Biosystems) using the Veriti™ 96-Well Thermal Cycler (Applied Biosystems). Real Time quantitative PCR was performed in duplicate using SYBR™ Select Master Mix (Applied Biosystems) and the QuantStudio™ 7 Flex Real-Time PCR System (Applied Biosystems). Data was normalised using the comparative CT method against the expression of *Ppia* (which was unaffected by experimental group or sex) and relative to expression in the male control group. Primer sequences are shown in Table 2.

Table 2. Primer sequences for RT-PCR.

Gene	Forward 5'-3'	Reverse 5'-3'
<i>Cd11c</i>	TGCTGTTGGGGTTGTTCTG	CGAACTCAGCACCGTCCAT
<i>F4/80</i>	CACTCCAAGATGGGTAACATCCCTGCCATCAACTCATGATAACCCT	
<i>Ppia</i>	GTCCAGGAATGGCAAGACCA	GGGTAAATGCCCGCAAGTC

4.3 Histological analysis

Formalin-fixed gonadal adipose tissue was processed, embedded, sectioned and 3 µm sections were stained with haematoxylin and eosin (H&E). Whole sections were scanned using the Axioscan digital slide scanner (Zeiss, Germany). Images were analysed using HALO analysis software (Indica labs, USA) using DenseNet AI Plugin classifiers ('crown-like structures' or CLS analysis) and the Vacuole Quantification tool (adipocyte cell size) adapted to the H&E-stained WAT sections. Estimated adipocyte number was calculated based on methods previously described [28] by dividing the total volume of gonadal WAT (estimated from the tissue weight and density of rodent visceral WAT) by the mean adipocyte volume derived from the cross-sectional area measured by HALO. The percentage adipocytes surrounded by CLS, a marker of adipocyte death [44], was calculated by normalising the number of CLS by the number of adipocytes per section.'

4.4 Intraperitoneal glucose tolerance test

Following an overnight fast, offspring were injected intraperitoneally with 1g/kg glucose solution. Blood glucose was measured from the tail vein at baseline, 15, 30, 60 and 120 minutes post-injection (AlphaTRAK2, Zoetis, USA). The area under the glucose excursion curve during the glucose tolerance test was computed using the trapezoid rule in Prism 8.0 (GraphPad, USA).

2.5 Serum analysis

Terminal blood was collected following a 16 hour fast by cardiac puncture. Serum was collected after centrifugation at 3000g and stored at -80°C. Serum insulin was measured using the Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem, USA).

2.6 Statistical analysis

Data are presented as means ± SEM and were analysed using Prism 8.0 software (GraphPad) using one-way ANOVA, two-way ANOVA or non-parametric alternatives where appropriate. Outliers were determined by the Grubb's method and excluded as described in the figure legends. A p-value of p<0.05 was considered statistically significant. In all cases n refers to the number of independent litters represented.

Author Contributions: Conceptualization, SEO; Formal analysis, JMS <u>and CEA</u> ; Funding acquisition, SEO; Investigation, JMS, HLB, TJA and DSF-T; Methodology, HLB, DSF-T and SEO; Project administration, JMS and SEO; Supervision, SEO; Visualization, JMS and SEO; Writing – original draft, JMS; Writing – review & editing, HLB, DSF-T <u>and CEA</u> .	428 429 430 431
Funding: This research was funded by the British Heart Foundation, grants RG/17/12/33167, PG/13/46/30329 and studentship to JMS FS/16/53/32729, and the Medical Research Council, grant MC_UU_00014/4 <u>and MR/T016701/1</u> .	432 433 434
Institutional Review Board Statement: All mouse work was performed according to the Home Office Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012, after ethical review by the University of Cambridge Animal and Welfare Ethical Review Board.	435 436 437
Data Availability Statement: As the manuscript does not include any omics data, the data presented in this study are available on request from the corresponding author as appropriate (such as for use in meta-analyses) following publication. The data are not publicly available	438 439 440
Acknowledgments: The authors would like to acknowledge and thank Claire Custance for expert technical assistance.	441 442
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.	443 444 445
References	446
[1] Davies, S.C., 2015. Annual Report of the Chief Medical Officer, 2014, The Health of the 51%: Women. London.	447
[2] Poirier, P., Giles, T.D., Bray, G.A., Hong, Y., Stern, J.S., Pi-Sunyer, F.X., et al., 2006. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> 26(5): 968–76, Doi: 10.1161/01.ATV.0000216787.85457.f3.	448 449 450
[3] Drake, A.J., Reynolds, R.M., 2010. Impact of maternal obesity on offspring obesity and cardiometabolic disease risk. <i>Reproduction</i> 140(3): 387–98, Doi: 10.1530/REP-10-0077.	451 452
[4] Chu, S.Y., Callaghan, W.M., Kim, S.Y., Schmid, C.H., Lau, J., England, L.J., et al., 2007. Maternal obesity and risk of gestational diabetes mellitus. <i>Diabetes Care</i> 30(8): 2070–6, Doi: 10.2337/dc06-2559a.	453 454
[5] Cesta, C.E., Cohen, J.M., Pazzagli, L., Bateman, B.T., Bröms, G., Einarsdóttir, K., et al., 2019. Antidiabetic medication use during pregnancy: An international utilization study. <i>BMJ Open Diabetes Research and Care</i> 7(1), Doi: 10.1136/bmjdrc-2019-000759.	455 456 457
[6] National Institute for Health and Care Excellence., 2015. Diabetes in pregnancy : management from preconception to the postnatal period (NG3). NICE (February): 2–65, Doi: 978-1-4731-0993-3.	458 459
[7] Barrett, H.L., Gatford, K.L., Houda, C.M., De Blasio, M.J., McIntyre, H.D., Callaway, L.K., et al., 2013. Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the metformin in gestational diabetes (MiG) trial: responses to maternal metformin versus insulin treatment. <i>Diabetes Care</i> 36(3): 529–36, Doi: 10.2337/dc12-1097.	460 461 462
[8] Syngelaki, A., Nicolaides, K.H., Balani, J., Hyer, S., Akolekar, R., Kotecha, R., et al., 2016. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. <i>New England Journal of Medicine</i> 374(5): 434–43, Doi: 10.1056/NEJMoa1509819.	463 464
[9] Eyal, S., Easterling, T.R., Carr, D., Umans, J.G., Miodovnik, M., Hankins, G.D.V., et al., 2010. Pharmacokinetics of metformin during pregnancy. <i>Drug Metabolism and Disposition</i> 38(5): 833–40, Doi: 10.1124/dmd.109.031245.	465 466
[10] Rowan, J.A., Rush, E.C., Plank, L.D., Lu, J., Obolonkin, V., Coat, S., et al., 2018. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. <i>BMJ Open Diabetes Research & Care</i> 6(1): e000456, Doi: 10.1136/bmjdrc-2017-000456.	467 468 469
[11] Rø, B., Ludvigsen, V., Carlsen, M., Vanky, E., 2012. Growth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> 72(7): 570, Doi: 10.3109/00365513.2012.712319.	470 471 472

- [12] Hanem, L.G.E., Salvesen, Ø., Juliusson, P.B., Carlsen, S.M., Nossum, M.C.F., Vaage, M.Ø., et al., 2019. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial. *The Lancet Child and Adolescent Health* 3(3): 166–74, Doi: 10.1016/S2352-4642(18)30385-7. 473
474
475
- [13] Hanem, L.G.E., Stridsklev, S., Júliusson, P.B., Salvesen, Ø., Roelants, M., Carlsen, S.M., et al., 2018. Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. *Journal of Clinical Endocrinology and Metabolism* 103(4): 1612–21, Doi: 10.1210/jc.2017-02419. 476
477
478
- [14] Panagiotopoulou, O., Syngelaki, A., Georgopoulos, G., Simpson, J., Akolekar, R., Shehata, H., et al., 2020. Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. *American Journal of Obstetrics and Gynecology* 223(2): 246.e1–246.e10, Doi: 10.1016/j.ajog.2020.01.054. 479
480
481
- [15] Tertti, K., Toppari, J., Virtanen, H.E., Sadov, S., Rönnemaa, T., 2016. Metformin treatment does not affect testicular size in offspring born to mothers with gestational diabetes. *Review of Diabetic Studies* 13(1): 59–65, Doi: 10.1900/RDS.2016.13.59. 482
483
- [16] Samuelsson, A.M., Matthews, P.A., Argenton, M., Christie, M.R., McConnell, J.M., Jansen, E.H.J.M., et al., 2008. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: A novel murine model of developmental programming. *Hypertension* 51(2): 383–92, Doi: 10.1161/HYPERTENSIONAHA.107.101477. 484
485
486
- [17] Fernandez-Twinn, D.S., Gascoin, G., Musial, B., Carr, S., Duque-Guimaraes, D., Blackmore, H.L., et al., 2017. Exercise rescues obese mothers' insulin sensitivity, placental hypoxia and male offspring insulin sensitivity. *Scientific Reports* 7(March): 44650, Doi: 10.1038/srep44650. 487
488
489
- [18] Ingvorsen, C., Thysen, A.H., Fernandez-Twinn, D., Nordby, P., Nielsen, K.F., Ozanne, S.E., et al., 2014. Effects of pregnancy on obesity-induced inflammation in a mouse model of fetal programming. *International Journal of Obesity (2005)* 38(August 2013): 1–28, Doi: 10.1038/ijo.2014.69. 490
491
492
- [19] Alfaradhi, M.Z., Kusinski, L.C., Fernandez-Twinn, D.S., Pantaleão, L.C., Carr, S.K., Ferland-McCollough, D., et al., 2016. Maternal obesity in pregnancy developmentally programs adipose tissue inflammation in young, lean male mice offspring. *Endocrinology* 157(11): 4246–56, Doi: 10.1210/en.2016-1314. 493
494
495
- [20] de Almeida Faria, J., Duque-Guimarães, D., Carpenter, A.A.M., Loche, E., Ozanne, S.E., 2017. A post-weaning obesogenic diet exacerbates the detrimental effects of maternal obesity on offspring insulin signaling in adipose tissue. *Scientific Reports* 7: 44949, Doi: 10.1038/srep44949. 496
497
498
- [21] Vega, C.C., Reyes-Castro, L.A., Bautista, C.J., Larrea, F., Nathanielsz, P.W., Zambrano, E., 2015. Exercise in obese female rats has beneficial effects on maternal and male and female offspring metabolism. *International Journal of Obesity* 39(4): 712–9, Doi: 10.1038/ijo.2013.150. 499
500
501
- [22] Stanford, K.I., Lee, M.-Y.Y., Getchell, K.M., So, K., Hirshman, M.F., Goodyear, L.J., 2015. Exercise Before and During Pregnancy Prevents the deleterious Effects of Maternal High-Fat Feeding on Metabolic Health of Male Offspring. *Diabetes* 64(2): 427–33, Doi: 10.2337/db13-1848. 502
503
504
- [23] Tong, J.F., Yan, X., Zhao, J.X., Zhu, M.J., Nathanielsz, P.W., Du, M., 2011. Metformin mitigates the impaired development of skeletal muscle in the offspring of obese mice. *Nutrition and Diabetes* 1(5): e7, Doi: 10.1038/nutd.2011.3. 505
506
- [24] Salomäki-Myftari, H., Vähätalo, L.H., Ailanen, L., Pietilä, S., Laiho, A., Hänninen, A., et al., 2016. Neuropeptide Y overexpressing female and male mice show divergent metabolic but not gut microbial responses to prenatal metformin exposure. *PLoS ONE* 11(9): e0163805, Doi: 10.1371/journal.pone.0163805. 507
508
509
- [25] Salomäki, H., Heinäniemi, M., Vähätalo, L.H., Ailanen, L., Eerola, K., Ruohonen, S.T., et al., 2014. Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring. *PLoS ONE* 9(12): e115778, Doi: 10.1371/journal.pone.0115778. 510
511
512
- [26] Salomäki, H., Vähätalo, L.H., Laurila, K., Jäppinen, N.T., Penttinen, A.M., Ailanen, L., et al., 2013. Prenatal Metformin Exposure in Mice Programs the Metabolic Phenotype of the Offspring during a High Fat Diet at Adulthood. *PLoS ONE* 8(2), 513
514

	Doi: 10.1371/journal.pone.0056594.	515
[27]	Gregg, B.E., Botezatu, N., Brill, J.D., Hafner, H., Vadrevu, S., Satin, L.S., et al., 2018. Gestational exposure to metformin programs improved glucose tolerance and insulin secretion in adult male mouse offspring. <i>Scientific Reports</i> 8(1): 5745, Doi: 10.1038/s41598-018-23965-4.	516
[28]	Carlson, Z., Hafner, H., Mulcahy, M., Bullock, K., Zhu, A., Bridges, D., et al., 2020. Lactational Metformin Exposure Programs Offspring White Adipose Tissue Glucose Homeostasis and Resilience to Metabolic Stress in a Sex-Dependent Manner. <i>American Journal of Physiology-Endocrinology and Metabolism</i> 318(5): E600–12, Doi: 10.1152/ajpendo.00473.2019.	518
[29]	Álvarez, D., Ceballo, K., Olguín, S., Martínez-Pinto, J., Maliqueo, M., Fernandois, D., et al., 2018. Prenatal metformin treatment improves ovarian function in offspring of obese rats. <i>Journal of Endocrinology</i> 239(3): 325–38, Doi: 10.1530/JOE-18-0352.	522
[30]	Armitage, J.A., Khan, I.Y., Taylor, P.D., Nathanielsz, P.W., Poston, L., 2004. Developmental programming of the metabolic syndrome by maternal nutritional imbalance: How strong is the evidence from experimental models in mammals? <i>Journal of Physiology</i> : 355–77, Doi: 10.1113/jphysiol.2004.072009.	525
[31]	Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., Gerich, J.E., 1995. Metabolic Effects of Metformin in Non-Insulin-Dependent Diabetes Mellitus. <i>New England Journal of Medicine</i> 333(9): 550–4, Doi: 10.1056/NEJM199508313330903.	529
[32]	Butalia, S., Gutierrez, L., Lodha, A., Aitken, E., Zakariasen, A., Donovan, L., 2017. Short- and long-term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta-analysis. <i>Diabetic Medicine</i> 34(1): 27–36, Doi: 10.1111/dme.13150.	530
[33]	Løvvik, T.S., Carlsen, S.M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., et al., 2019. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. <i>The Lancet Diabetes and Endocrinology</i> 7(4): 256–66, Doi: 10.1016/S2213-8587(19)30002-6.	533
[34]	Barbour, L.A., Scifres, C., Valent, A.M., Friedman, J.E., Buchanan, T.A., Coustan, D., et al., 2018. A cautionary response to SMFM statement: pharmacological treatment of gestational diabetes. <i>American Journal of Obstetrics and Gynecology</i> 219(4): 367.e1-367.e7, Doi: 10.1016/j.ajog.2018.06.013.	536
[35]	Rajasingam, D., Seed, P.T., Briley, A.L., Shennan, A.H., Poston, L., 2009. A prospective study of pregnancy outcome and biomarkers of oxidative stress in nulliparous obese women. <i>American Journal of Obstetrics and Gynecology</i> 200(4): 395.e1-395.e9, Doi: 10.1016/j.ajog.2008.10.047.	539
[36]	Loche, E., Blackmore, H.L., Carpenter, A.A., Beeson, J.H., Pinnock, A., Ashmore, T.J., et al., 2018. Maternal diet-induced obesity programmes cardiac dysfunction in male mice independently of post-weaning diet. <i>Cardiovascular Research</i> 114(10): 1372–84, Doi: 10.1093/cvr/cvy082.	542
[37]	de Barros Mucci, D., Kusinski, L.C., Wilsmore, P., Loche, E., Pantaleão, L.C., Ashmore, T.J., et al., 2020. Impact of maternal obesity on placental transcriptome and morphology associated with fetal growth restriction in mice. <i>International Journal of Obesity</i> : 1–10, Doi: 10.1038/s41366-020-0561-3.	545
[38]	Ravelli, A.C.J., Van Der Meulen, J.H.P., Michels, R.P.J., Osmond, C., Barker, D.J.P., Hales, C.N., et al., 1998. Glucose tolerance in adults after prenatal exposure to famine. <i>Lancet</i> 351(9097): 173–7, Doi: 10.1016/S0140-6736(97)07244-9.	549
[39]	Ravelli, A.C.J., Van Der Meulen, J.H.P., Osmond, C., Barker, D.J.P., Bleker, O.P., 1999. Obesity at the age of 50 y in men and women exposed to famine prenatally. <i>American Journal of Clinical Nutrition</i> 70(5): 811–6, Doi: 10.1093/ajcn/70.5.811.	551
[40]	Roseboom, T.J., Van der Meulen, J.H.P., Osmond, C., Barker, D.J.P., Ravelli, A.C.J., Schroeder-Tanka, J.M., et al., 2000. Coronary heart disease after prenatal exposure to the Dutch famine, 1944–45. <i>Heart</i> 84(6): 595–8, Doi: 10.1136/heart.84.6.595.	553
[41]	Roseboom, T.J., Van der Meulen, J.H.P., Osmond, C., Barker, D.J.P., Ravelli, A.C.J., Bleker, O.P., 2000. Plasma lipid profiles in adults after prenatal exposure to the Dutch famine. <i>American Journal of Clinical Nutrition</i> 72(5): 1101–6, Doi: 10.1093/ajcn/72.5.1101.	555

- [42] Berends, L.M., Fernandez-Twinn, D.S., Martin-Gronert, M.S., Cripps, R.L., Ozanne, S.E., 2013. Catch-up growth following intra-uterine growth-restriction programmes an insulin-resistant phenotype in adipose tissue. International Journal of Obesity 37(8): 1051–7, Doi: 10.1038/ijo.2012.196. 557
558
559
- [43] Berends, L.M., Dearden, L., Tung, Y.C.L., Voshol, P., Fernandez-Twinn, D.S., Ozanne, S.E., 2018. Programming of central and peripheral insulin resistance by low birthweight and postnatal catch-up growth in male mice. Diabetologia 61(10): 2225–34, 560
561
562
- [44] Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., et al., 2005. Adipocyte death defines macrophage 563
localization and function in adipose tissue of obese mice and humans. Journal of Lipid Research 46(11): 2347–55, Doi: 564
10.1194/jlr.M500294-JLR200. 565
- [45] Strissel, K.J., Stancheva, Z., Miyoshi, H., Perfield, J.W., DeFuria, J., Jick, Z., et al., 2007. Adipocyte death, adipose tissue 566
remodeling, and obesity complications. Diabetes 56(12): 2910–8, Doi: 10.2337/db07-0767. 567
- [46] Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., et al., 2003. Chronic inflammation in fat plays a crucial role in 568
the development of obesity-related insulin resistance. Journal of Clinical Investigation 112(12): 1821–30, Doi: 10.1172/jci19451. 569
- [47] Varghese, M., Griffin, C., McKernan, K., Eter, L., Lanzetta, N., Agarwal, D., et al., 2019. Sex differences in inflammatory 570
responses to adipose tissue lipolysis in diet-induced obesity. Endocrinology 160(2): 293–312, Doi: 10.1210/en.2018-00797. 571
- [48] Yokomizo, H., Inoguchi, T., Sonoda, N., Sakaki, Y., Maeda, Y., Inoue, T., et al., 2014. Maternal high-fat diet induces insulin 572
resistance and deterioration of pancreatic β -cell function in adult offspring with sex differences in mice. American Journal of 573
Physiology - Endocrinology and Metabolism 306(10): E1163–75, Doi: 10.1152/ajpendo.00688.2013. 574
- [49] Aiken, C.E., Ozanne, S.E., 2013. Sex differences in developmental programming models. Reproduction 145(1): 145–6, Doi: 575
10.1530/REP-11-0489. 576
- [50] Dearden, L., Bouret, S.G., Ozanne, S.E., 2018. Sex and gender differences in developmental programming of metabolism. 577
Molecular Metabolism 15: 8–19, Doi: 10.1016/j.molmet.2018.04.007. 578
- [51] Tarry-Adkins, J.L., Aiken, C.E., Ozanne, S.E., 2019. Neonatal, infant, and childhood growth following metformin versus 579
insulin treatment for gestational diabetes: A systematic review and meta-analysis. PLoS Medicine 16(8): e1002848, Doi: 580
10.1371/journal.pmed.1002848. 581
- [52] Rowan, J.A., Rush, E.C., Obolonkin, V., Battin, M., Woudles, T., Hague, W.M., 2011. Metformin in gestational diabetes: The 582
offspring follow-up (MiG TOFU) - Body composition at 2 years of age. Diabetes Care 34(10): 2279–84, Doi: 10.2337/dc11-0660. 583
- [53] Chiswick, C.A., Reynolds, R.M., Denison, F.C., Drake, A.J., Forbes, S., Newby, D.E., et al., 2015. Effect of metformin on 584
maternal and fetal outcomes in obese pregnant women (EMPOWaR): A randomised, double-blind, placebo-controlled trial. 585
The Lancet Diabetes and Endocrinology 3(10): 778–86, Doi: 10.1016/S2213-8587(15)00219-3. 586
587